tyrphostin 51

Also Known As:

tyrphostin-51

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzylidene Compounds: 10
        Tyrphostins: 183
        tyrphostin 51: 3
- Nitriles: 227
  - Tyrphostins: 183
    - tyrphostin 51: 3
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinoxalines: 324
      - Tyrphostins: 183
        tyrphostin 51: 3

Experts

1.	Chao, Jane C J: 1 article (02/2004)
2.	Chen, Sheng-Hsuan: 1 article (02/2004)
3.	Peng, Wen Li: 1 article (02/2004)
4.	Breuiller-Fouche, M: 1 article (05/2001)
5.	Chapron, C: 1 article (05/2001)
6.	Dallot, E: 1 article (05/2001)
7.	Eude, I: 1 article (05/2001)
8.	Ferre, F: 1 article (05/2001)
9.	Vacher-Lavenu, M C: 1 article (05/2001)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 02/15/2004 - "The data suggest that EGF antibody and tyrphostin 51 can inhibit the action of EGF on apoptosis in human colorectal cancer cells through down-regulation of EGF receptor and p21 expression." 02/15/2004 - "The study investigated if EGF signaling inhibitors, EGF antibody and tyrphostin 51 (a tyrosine kinase inhibitor), mediated the action of EGF on apoptosis and the expression of EGF receptors and p21 (a cyclin-dependent kinase inhibitor) of human colorectal cancer cells. "
2.	Leiomyoma (Uterine Fibroids) 05/01/2001 - "ET-1 on its own was unable to stimulate DNA synthesis but potentiated the leiomyoma cell growth effects of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), IGF-I and IGF-II. The failure of a protein tyrosine kinase (PTK) inhibitor, tyrphostin 51, to affect the potentiating effect of ET-1, supports the hypothesis of non-involvement of PTK in this process. "
3.	Body Weight (Weight, Body) 11/01/1995 - "One of the young and aged groups of rats was also injected (i.p.) with the Tyr-k inhibitor tyrphostin-51 (300 micrograms/kg body weight) 60 minutes before injury. "
4.	Adenocarcinoma 02/15/2004 - "Human colorectal adenocarcinoma cells (SW480) were incubated with 0.6 mL/L dimethyl sulfoxide (DMSO, the control group), 225 ng/mL (37.5 nmol/L) EGF in 0.6 mL/L DMSO, 225 ng/mL EGF+2.5 microg/mL (17 nmol/L) EGF antibody in 0.6 mL/L DMSO, or 225 ng/mL EGF+215 ng/mL (0.8 micromol/L) tyrphostin 51 in 0.6 mL/L DMSO. "

Related Drugs and Biologics

1.	Epidermal Growth Factor (EGF)
2.	ErbB Receptors (EGF Receptor)
3.	Cyclin-Dependent Kinases (cdk Proteins)
4.	Tyrosine Kinase Inhibitors
5.	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
6.	Protein-Tyrosine Kinases (Tyrosine Kinase)
7.	Insulin-Like Growth Factor II (Somatomedin A)
8.	Insulin-Like Growth Factor I (IGF-1)
9.	DNA (Deoxyribonucleic Acid)
10.	Dimethyl Sulfoxide (DMSO)